Imagine your joint cartilage is like a worn-out brake pad in a car. Instead of just replacing the whole part with metal, this project grows a new, natural pad using cells from your own nose. This custom-made biological patch is then implanted in the knee to fix the damage and stop the disease from getting worse.
Current osteoarthritis treatments only manage pain or replace joints with metal, leaving 500 million people without a way to actually repair or reverse cartilage damage.
A combined ATMP called N-TEC, consisting of autologous nasal chondrocytes and a collagen membrane for joint reconstruction.
If you are an ATMP developer dealing with the lack of disease-modifying OA treatments — this project developed N-TEC, a tissue-engineered implant that uses autologous nasal chondrocytes to biologically reconstruct the joint. This provides a regenerative alternative to total joint replacement.
If you are an implant manufacturer dealing with the limitations of metal knee replacements — this project developed a combined ATMP using a collagen membrane and living cells. This allows for a biological repair of the patellofemoral joint rather than a mechanical substitute.
If you are a clinic dealing with a growing patient base of 500 million people with OA — this project developed a Phase II tested therapy to restore mobility. This could reduce the long-term need for expensive knee arthroplasty surgeries.
Based on available project data, specific pricing is not provided, but health economists are assessing cost-effectiveness and access pathways.
The consortium includes 4 SMEs and 6 industry partners who are developing a road map towards commercial exploitation and centralized marketing authorization.
Based on available project data, the project involves a multidisciplinary consortium including SMEs focused on the commercial exploitation road map, though specific licensing terms are not listed.
The product is classified as a combined ATMP, and the project includes experts in regulatory science to navigate the path toward centralized marketing authorization.
The project runs from 2024-01-01 to 2029-12-31, with a Phase II trial currently underway to assess efficacy.
The consortium is highly commercially oriented, with a 32% industry ratio comprising 6 industry partners and 4 SMEs. With 19 partners across 10 countries, the group balances academic research (7 universities, 2 research institutes) with practical application in regulatory science and health economics, indicating a strong push toward market entry rather than just basic research.
Contact Fondazione Policlinico Universitario Campus Bio Medico in Italy
Contact us to connect with the ENCANTO consortium for licensing opportunities.
